ClinicalTrials.gg

Program

BMS-986525

A development code.

Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.

Furthest: phase 2, since Jan 6, 20261 company-led study, 1 open or runningNext primary completion: Apr 23, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 2since Jan 6, 2026Jan 6, 2026Apr 23, 2029phase 2 · NCT07325136
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986525, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2026First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT07325136 · 240 planned · United States, China, Italy and more

Ahead

  1. Apr 23, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07325136

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07325136Small Cell Lung Carcinoma · United States, China, Italy and more2RecruitingApr 23, 2029240

How it is read

Names in the registry

  • “BMS-986525”, 1 entry

Codes read as this program: BMS986525.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.